M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026
M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover pharminent July 16, 2026
Clinical Data AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug pharminent July 15, 2026
Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance pharminent July 15, 2026
Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026
Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026
Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project pharminent July 1, 2026
Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project pharminent June 9, 2026
Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA pharminent June 5, 2026
M&A / Deals Deep Science Ventures and MDC partner to accelerate brain treatments pharminent June 2, 2026
Clinical Data Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate pharminent May 15, 2026
Pipeline Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism pharminent May 14, 2026
Regulatory Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy pharminent May 8, 2026
Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS pharminent May 5, 2026
Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026
Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation pharminent May 1, 2026
Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia pharminent April 30, 2026
